Does ACS Endorsement of Cologuard Shape the Bull Case for Abbott Laboratories (ABT) in Cancer Screening?

Earlier this week, the American Cancer Society updated its colorectal cancer screening guidelines, reaffirming Abbott’s Cologuard and Cologuard Plus as preferred noninvasive options for average‐risk adults aged 45 and older on a three‐year testing interval. The endorsement, combined with Abbott’s planned commercialization of a blood‐based colorectal cancer test pending FDA approval, reinforces its broad footprint across noninvasive cancer screening. We’ll now explore how reaffirmed ACS guideline preference for Cologuard and Cologuard Plus influences Abbott’s broader investment narrative and growth drivers.

Does ACS Endorsement of Cologuard Shape the Bull Case for Abbott Laboratories (ABT) in Cancer Screening?. Earlier this week, the American Cancer Society updated its colorectal cancer screening guidelines, reaffirming Abbott’s Cologuard and Cologuard Plus as preferred noninvasive options for average‐risk adults aged 45 and older on a three‐year testing interval. The endorsement, combined with Abbott’s planned commercialization of a blood‐based colorectal cancer test pending FDA approval, reinforces its broad footprint across noninvasive cancer screening. We’ll now explore how reaffirmed ACS guideline preference for Cologuard and Cologuard Plus influences Abbott’s broader investment narrative and growth drivers. AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery . The best pa...